NIH [to 18 February 2017]

NIH [to 18 February 2017]
http://www.nih.gov/news-events/news-releases

Thursday, February 16, 2017
Investigational PfSPZ malaria vaccine demonstrates considerable protection in Malian adults for duration of malaria season
An investigational malaria vaccine given intravenously was well-tolerated and protected a significant proportion of healthy adults against infection with Plasmodium falciparum malaria — the deadliest form of the disease — for the duration of the malaria season, according to new findings published in the February 15th issue of the journal Lancet Infectious Diseases. The study participants live in Mali, Africa, where they are naturally exposed to the parasite.
The investigational vaccine, known as the PfSPZ Vaccine, contains live but weakened sporozoites, the form of the parasite that infects humans, and was developed by scientists at Sanaria Inc., of Rockville, Maryland. The study was conducted by researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the University of Science, Techniques, and Technologies of Bamako (USTTB), Mali, one of NIAID’s International Centers of Excellence in Malaria Research…

NIH research helps explain how antibody treatment led to sustained remission of HIV-like virus
February 15, 2017 — Research presents a new target for HIV prevention and treatment, and sheds light on how HIV develops.